Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index

Ameya R. Kirtane, Henry L. Wong, Bharath Raja Guru, Lev G. Lis, Gunda I. Georg, Vadim J. Gurvich, Jayanth Panyam

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Several promising anticancer drug candidates have been sidelined owing to their poor physicochemical properties or unfavorable pharmacokinetics, resulting in high overall cost of drug discovery and development. Use of alternative formulation strategies that alleviate these issues can help advance new molecules to the clinic at a significantly lower cost. Tylocrebrine is a natural product with potent anticancer activity. Its clinical trial was discontinued following the discovery of severe central nervous system toxicities. To improve the safety and potency of tylocrebrine, we formulated the drug in polymeric nanoparticles targeted to the epidermal growth factor receptor (EGFR) overexpressed on several types of tumors. Through in vitro studies in different cancer cell lines, we found that EGFR targeted nanoparticles were significantly more effective in killing tumor cells than the free drug. In vivo pharmacokinetic studies revealed that encapsulation in nanoparticles resulted in lower brain penetration and enhanced tumor accumulation of the drug. Further, targeted nanoparticles were characterized by significantly enhanced tumor growth inhibitory activity in a mouse xenograft model of epidermoid cancer. These results suggest that the therapeutic index of drugs that were previously considered unusable could be significantly improved by reformulation. Application of novel formulation strategies to previously abandoned drugs provides an opportunity to advance new molecules to the clinic at a lower cost. This can significantly increase the repertoire of treatment options available to cancer patients.

Original languageEnglish
Pages (from-to)2912-2923
Number of pages12
JournalMolecular Pharmaceutics
Volume12
Issue number8
DOIs
Publication statusPublished - 03-08-2015

Fingerprint

Epidermal Growth Factor Receptor
Nanoparticles
Neoplasms
Pharmaceutical Preparations
Costs and Cost Analysis
Therapeutics
Pharmacokinetics
Drug Discovery
tylocrebrine
Biological Products
Heterografts
Central Nervous System
Clinical Trials
Safety
Cell Line
Brain
Growth

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Kirtane, Ameya R. ; Wong, Henry L. ; Guru, Bharath Raja ; Lis, Lev G. ; Georg, Gunda I. ; Gurvich, Vadim J. ; Panyam, Jayanth. / Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index. In: Molecular Pharmaceutics. 2015 ; Vol. 12, No. 8. pp. 2912-2923.
@article{92cca454491b466c8419c78af2078ab8,
title = "Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index",
abstract = "Several promising anticancer drug candidates have been sidelined owing to their poor physicochemical properties or unfavorable pharmacokinetics, resulting in high overall cost of drug discovery and development. Use of alternative formulation strategies that alleviate these issues can help advance new molecules to the clinic at a significantly lower cost. Tylocrebrine is a natural product with potent anticancer activity. Its clinical trial was discontinued following the discovery of severe central nervous system toxicities. To improve the safety and potency of tylocrebrine, we formulated the drug in polymeric nanoparticles targeted to the epidermal growth factor receptor (EGFR) overexpressed on several types of tumors. Through in vitro studies in different cancer cell lines, we found that EGFR targeted nanoparticles were significantly more effective in killing tumor cells than the free drug. In vivo pharmacokinetic studies revealed that encapsulation in nanoparticles resulted in lower brain penetration and enhanced tumor accumulation of the drug. Further, targeted nanoparticles were characterized by significantly enhanced tumor growth inhibitory activity in a mouse xenograft model of epidermoid cancer. These results suggest that the therapeutic index of drugs that were previously considered unusable could be significantly improved by reformulation. Application of novel formulation strategies to previously abandoned drugs provides an opportunity to advance new molecules to the clinic at a lower cost. This can significantly increase the repertoire of treatment options available to cancer patients.",
author = "Kirtane, {Ameya R.} and Wong, {Henry L.} and Guru, {Bharath Raja} and Lis, {Lev G.} and Georg, {Gunda I.} and Gurvich, {Vadim J.} and Jayanth Panyam",
year = "2015",
month = "8",
day = "3",
doi = "10.1021/acs.molpharmaceut.5b00173",
language = "English",
volume = "12",
pages = "2912--2923",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "8",

}

Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index. / Kirtane, Ameya R.; Wong, Henry L.; Guru, Bharath Raja; Lis, Lev G.; Georg, Gunda I.; Gurvich, Vadim J.; Panyam, Jayanth.

In: Molecular Pharmaceutics, Vol. 12, No. 8, 03.08.2015, p. 2912-2923.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index

AU - Kirtane, Ameya R.

AU - Wong, Henry L.

AU - Guru, Bharath Raja

AU - Lis, Lev G.

AU - Georg, Gunda I.

AU - Gurvich, Vadim J.

AU - Panyam, Jayanth

PY - 2015/8/3

Y1 - 2015/8/3

N2 - Several promising anticancer drug candidates have been sidelined owing to their poor physicochemical properties or unfavorable pharmacokinetics, resulting in high overall cost of drug discovery and development. Use of alternative formulation strategies that alleviate these issues can help advance new molecules to the clinic at a significantly lower cost. Tylocrebrine is a natural product with potent anticancer activity. Its clinical trial was discontinued following the discovery of severe central nervous system toxicities. To improve the safety and potency of tylocrebrine, we formulated the drug in polymeric nanoparticles targeted to the epidermal growth factor receptor (EGFR) overexpressed on several types of tumors. Through in vitro studies in different cancer cell lines, we found that EGFR targeted nanoparticles were significantly more effective in killing tumor cells than the free drug. In vivo pharmacokinetic studies revealed that encapsulation in nanoparticles resulted in lower brain penetration and enhanced tumor accumulation of the drug. Further, targeted nanoparticles were characterized by significantly enhanced tumor growth inhibitory activity in a mouse xenograft model of epidermoid cancer. These results suggest that the therapeutic index of drugs that were previously considered unusable could be significantly improved by reformulation. Application of novel formulation strategies to previously abandoned drugs provides an opportunity to advance new molecules to the clinic at a lower cost. This can significantly increase the repertoire of treatment options available to cancer patients.

AB - Several promising anticancer drug candidates have been sidelined owing to their poor physicochemical properties or unfavorable pharmacokinetics, resulting in high overall cost of drug discovery and development. Use of alternative formulation strategies that alleviate these issues can help advance new molecules to the clinic at a significantly lower cost. Tylocrebrine is a natural product with potent anticancer activity. Its clinical trial was discontinued following the discovery of severe central nervous system toxicities. To improve the safety and potency of tylocrebrine, we formulated the drug in polymeric nanoparticles targeted to the epidermal growth factor receptor (EGFR) overexpressed on several types of tumors. Through in vitro studies in different cancer cell lines, we found that EGFR targeted nanoparticles were significantly more effective in killing tumor cells than the free drug. In vivo pharmacokinetic studies revealed that encapsulation in nanoparticles resulted in lower brain penetration and enhanced tumor accumulation of the drug. Further, targeted nanoparticles were characterized by significantly enhanced tumor growth inhibitory activity in a mouse xenograft model of epidermoid cancer. These results suggest that the therapeutic index of drugs that were previously considered unusable could be significantly improved by reformulation. Application of novel formulation strategies to previously abandoned drugs provides an opportunity to advance new molecules to the clinic at a lower cost. This can significantly increase the repertoire of treatment options available to cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84938367454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938367454&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.5b00173

DO - 10.1021/acs.molpharmaceut.5b00173

M3 - Article

VL - 12

SP - 2912

EP - 2923

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 8

ER -